Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Pharma Recovery Takes Hold Amid Patent Expirations and Policy Uncertainty

Guavy AI Editorial Team
Instruments
MRK
Share

The pharmaceutical industry is experiencing a strong recovery in 2026, driven by innovation, robust quarterly performances, and positive regulatory updates.

However, there are headwinds such as slower-than-expected launches of newer therapies, patent expirations for blockbuster drugs, and policy and pricing uncertainty in major markets.

A recent $5 billion-plus deal is Merck's acquisition of Terns Pharmaceuticals, and other notable deals include Gilead's acquisition of Arcellx and Biogen's acquisition of Apellis Pharmaceuticals.

More on Stocks

Stocks 6m ago

Morgan Stanley Predicts Amazon Stock Could Double as AWS Reaches for $1 Trillion

Stocks 8m ago

Argyle Capital Partners Invests Heavily in Chevron Amid Major Discovery

Stocks 8m ago

BlackRock Takes $25 Billion Stake in Chevron Amid Rising Oil Prices

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy